
Beijing Bohui Innovation Biotechnology Group Co., Ltd. ("Bohui Group"), founded in 2001, has evolved into a high-tech biomedical enterprise that integrating R&D, production, sales, and after-sales service. Headquartered in Zhongguancun Life Science Park in Beijing, the company operates a 40, 000 square-meter comprehensive R&D center. In May 2012, Bohui Group was listed on the Shenzhen Stock Exchange ChiNext (Stock Code: 300318). In the field of in vitro diagnostics, the company's core products focus on maternal and child nutrition and infectious disease syndrome diagnosis. Based on atomic absorption spectrometry and mass spectrometry platforms, the company has deeply cultivated the field of trace element detection for two decades, building a leading brand in the industry. Relying on microfluidic technology, it has developed fully automated nucleic acid detection products known as "laboratories on a chip", focusing on infection detection. It has comprehensively laid out multiplex detection for reproductive tract infections (including HPV genotyping), diarrheal infections and respiratory infection syndromes, achieving full-scenario coverage of clinical testing. Rooted in China, the company is expanding globally.